Updated 22 October 2026. General educational information; individual assessment and prescribing must come from your clinical team.

Start with the care questions, not just the disease name

What does an EGPA diagnosis mean for your next appointment?

Eosinophilic granulomatosis with polyangiitis, usually shortened to EGPA, is an inflammatory illness that can involve small blood vessels and several organs. It was previously called Churg–Strauss syndrome. Asthma and sinus problems are common parts of the picture, but a care plan must look beyond breathing symptoms. The immediate questions are which organs are involved, whether any involvement threatens their function, and how the team will measure improvement. There is no single blood test that supplies all those answers. Many people with EGPA have a negative ANCA antibody result, so a negative result does not exclude the condition. Equally, symptoms resembling EGPA do not establish it without clinical assessment. This guide focuses on translating a diagnosis or suspected diagnosis into a coordinated assessment and monitoring plan, rather than offering a checklist for diagnosing yourself. [1]

Descriptions of EGPA sometimes divide its course into allergic, eosinophilic and vasculitic phases. These describe patterns that clinicians have observed, not a timetable that every person must follow. Not everyone experiences every phase. Asthma may have been present for years before another problem attracts attention, while another person may need several investigations close together. Do not wait for a supposed next stage before reporting a new symptom. A practical way to prepare is to make a timeline: when breathing or sinus trouble began, when blood tests changed, and when symptoms elsewhere appeared. Record dates approximately if exact dates are unavailable. Distinguish what you personally noticed from what a scan or clinician found. This helps your team understand the sequence without forcing your experience into a rigid disease story or assuming that one symptom predicts the next. [2]

How clinicians assemble the evidence

Assessment brings together the history, examination, laboratory results, imaging and sometimes a tissue biopsy. A high eosinophil count is an important clue, but it can occur in other illnesses and does not by itself identify EGPA. Your clinician may investigate alternative explanations before settling on a diagnosis. Bring older blood results and reports if you have them, together with a complete medication list and the dates that treatments changed. These records can explain why results obtained at different appointments do not look identical. Ask which findings strongly support EGPA, which remain uncertain, and what the next investigation is intended to resolve. If the diagnosis is still provisional, ask how symptoms will be managed safely while the investigation continues. You do not need to interpret every laboratory abbreviation yourself; you do need to know the next step and whom to contact if your condition changes. [3]

Understand what the tests can and cannot tell you

Eosinophils are one part of a blood count

A blood differential separates the different types of white blood cells rather than reporting only their total number. Eosinophils are involved in responses to parasites and in allergic inflammation, so an abnormal eosinophil result needs interpretation in context. A report may show a percentage, an absolute count, or both. When keeping your own record, copy the units and the laboratory reference range, not just the number highlighted in red. A percentage from one report is not directly interchangeable with an absolute count from another. Note whether the blood sample was taken before or after a treatment change, and let the clinician explain its significance. The useful question is not simply whether the count is normal today, but how it fits with symptoms, examination and the rest of the assessment. Do not change prescribed medicine to try to produce a more revealing blood result. [4]

An ANCA test looks for particular autoantibodies in blood. It can help clinicians investigate certain forms of vasculitis, but an antibody result is not a complete diagnosis or a map of organ involvement. Ask the team to explain the exact test reported and why it was ordered. A positive result must be interpreted alongside the clinical picture; other conditions can also be associated with these antibodies. Avoid comparing your value with someone else’s online result when the test method, units or diagnosis may differ. It is more useful to ask whether a result changes the plan for you and whether repeat testing will answer a specific clinical question. For broader background on the disease family, see our guide to ANCA-associated vasculitis. That background does not replace the EGPA-specific assessment of your own symptoms and organs. [5]

Classification criteria are not a home diagnostic score

The 2022 American College of Rheumatology and EULAR classification criteria were developed to distinguish EGPA within research populations. They are applied after a diagnosis of small or medium vessel vasculitis and after alternative explanations have been excluded. They are not designed to decide whether every person with asthma and eosinophilia has EGPA. Adding points from an internet list skips the clinical work that makes the classification meaningful. A person may need expert assessment even when a simplified score seems reassuring, and a high apparent score cannot prove a diagnosis on its own. If a report mentions classification criteria, ask whether the clinician is using them to describe an already assessed illness or discussing research eligibility. Keeping diagnosis and research classification separate prevents a numerical shortcut from replacing examination, consideration of competing diagnoses and assessment of the urgency of organ involvement. [6]

A biopsy examines a small sample of tissue for signs of disease. The most useful site depends on which organ appears involved and whether a sample can be obtained with an acceptable risk. Different specialists may contribute: a rheumatologist coordinates inflammatory disease care, while lung, kidney, nerve, skin or heart specialists investigate particular findings. Before an investigation, ask what it might confirm, what it cannot settle, and how the result would change treatment. Also ask who will communicate the result and when you should follow up if you have heard nothing. A test being requested does not necessarily mean permanent damage has already occurred; it may be part of finding out what is happening. Keep copies of the final reports rather than relying on a brief verbal description. This is especially helpful when assessment happens across more than one hospital or clinic. [7]

C-reactive protein, or CRP, is a marker of inflammation. It does not identify the location of inflammation or its cause. Infection and several inflammatory conditions can raise it, so a high result cannot automatically be labelled an EGPA flare. Your team may use trends as one piece of evidence, but a number should be read together with how you are feeling and what other tests show. When discussing a changed result, mention new symptoms, recent illnesses and changes in medicines or supplements. Ask whether the finding calls for repeat testing, a clinical review or another investigation rather than assuming that more immune suppression is the answer. It is reasonable to request a plain-language explanation of what is being monitored. A useful record links the date and result to the reason for the test and the clinician’s agreed next action. [8]

Build an organ-by-organ baseline

Lungs and airways: separate measurements from symptoms

Pulmonary function tests measure different aspects of breathing. Spirometry looks at how much air you can blow out and how quickly; other tests assess lung volumes or how effectively gas moves from the lungs into the blood. The tests your clinician chooses depend on the question being investigated. They do not all provide the same information, and they are not substitutes for imaging when imaging is needed. Ask which result will be used as your baseline and what change would justify an earlier review. Follow the testing service’s instructions about inhalers before the appointment rather than withholding them yourself. Mention if you are acutely unwell or cannot perform the breathing manoeuvre comfortably. Keeping the report alongside a short note about symptoms on the day can make a future comparison more useful than remembering only that your breathing test was described as good or bad. [9]

Asthma symptoms can vary over time and include wheeze, cough, breathlessness and chest tightness. Night waking, reduced usual activity or needing reliever treatment more often are reasons to discuss control with the asthma team. Having EGPA does not remove the need for good inhaler technique and an individual asthma plan. Conversely, assuming every episode of breathlessness is ordinary asthma can overlook another cause. Explain what is different from your familiar pattern, including the speed of onset and whether the usual prescribed relief helps. Severe or worsening breathing difficulty needs urgent help, not a routine appointment. Our overview of asthma patterns provides background terminology, but it cannot determine why breathing has changed in a person with EGPA. Take your inhalers to reviews so that their names and technique can be checked rather than relying on their colour alone. [10]

Heart assessment: know what was checked

An echocardiogram uses ultrasound to show the heart’s structure and how it is working. The common transthoracic scan uses a probe on the chest, while other types require different preparation. If you are referred for an echo, check which type is planned and follow the hospital’s instructions. The report is one part of a cardiac assessment, not a general certificate that every possible heart problem has been excluded. Ask which question the scan answered and whether the team needs any other information in view of your symptoms. Keep the date and result accessible, especially if several specialists are involved. If new symptoms develop later, tell the clinician when the previous scan was performed instead of assuming that an older normal result settles the new problem. Knowing the scope of a test is more useful than collecting tests without understanding their purpose. [11]

The 2021 ACR/Vasculitis Foundation guideline conditionally recommends an echocardiogram at EGPA diagnosis, even without heart symptoms. It also separates treatment of severe active EGPA from treatment of nonsevere disease. For severe disease, glucocorticoids with cyclophosphamide or rituximab are preferred over mepolizumab for remission induction. For active nonsevere disease, the guideline conditionally favours mepolizumab with glucocorticoids over certain conventional immunosuppressive combinations. These are specialist recommendations, not instructions to choose a medicine yourself, and the guideline predates the later benralizumab EGPA approval. Ask which manifestations determine your severity category and how the proposed treatment addresses them. A medicine appropriate for persistent airway disease is not automatically sufficient for an organ-threatening presentation. The same guideline also supports considering infection prevention in people receiving cyclophosphamide or rituximab. Discuss the specific prevention and monitoring plan rather than assuming every treatment has identical precautions. [12]

Nerves: describe function as well as pain

Peripheral nerve problems can change sensation, strength, balance or automatic body functions. Tingling and burning pain matter, but so do new difficulties lifting a foot, gripping an object or walking safely. Describe where the change is, whether one side differs from the other, when it began and whether it is progressing. A practical example is more informative than saying only that a limb feels odd: explain if your toes now catch on the floor or a previously easy task has become difficult. These observations help a clinician decide what examination or nerve testing is needed; they do not identify the cause by themselves. New or worsening weakness deserves prompt medical assessment rather than waiting to see whether it becomes painful. If sensation is reduced, ask about safe footwear, skin checks and falls prevention as part of the care plan, tailored to your actual functional limitations. [13]

Kidneys: urine and blood tests answer different questions

Blood tests used to estimate kidney filtration and urine tests for protein provide different information. Creatinine is a waste product used to estimate the glomerular filtration rate, while albumin in urine can indicate a problem with the kidney’s filtering barrier. Your EGPA team may also check urine for blood. Ask which kidney measurements belong in your monitoring plan and how the current result compares with your own previous results. Do not interpret one isolated number as proof of either normal kidneys or irreversible damage. An unexpected result may need confirmation or additional assessment, and the clinician must consider the surrounding circumstances. Keep the units with your records and ask who will review results obtained outside the specialist clinic. A blood appointment alone does not necessarily include the requested urine sample, so check the instructions before leaving the laboratory or surgery. [14]

An organ review should also include changes that are easy to omit when breathing dominates the conversation. Skin changes, digestive symptoms, hearing problems, eye symptoms, joint pain, fever, weight loss and unusual fatigue may be relevant to a vasculitis assessment. These symptoms can have many causes, and not every symptom in a person with EGPA is caused by EGPA. The useful approach is to report what changed rather than decide the diagnosis yourself. For a rash, note when it appeared and consider a dated photograph for your clinician if it is safe to take one. For digestive symptoms, describe duration, severity and any bleeding. For hearing or vision changes, state whether onset was sudden. A short structured account helps the team decide whether an organ needs investigation without turning a long symptom list into a collection of assumed complications. [15]

Know which changes cannot wait

Chest discomfort and sudden neurological changes

Sudden chest pain or pressure that does not go away, pain spreading to an arm, the jaw, back or neck, or chest pain accompanied by sweating, nausea, light-headedness or breathlessness needs emergency assessment. Call your local emergency number rather than waiting for a specialist to reply. The cause may or may not be related to EGPA, but that uncertainty is a reason to be assessed, not a reason to wait. Do not try to settle the cause by comparing the pain with descriptions online. If you can do so without delaying help, tell the emergency team that you have EGPA and which medicines you take. A prepared medication list is useful here. Symptoms that come and go also deserve medical advice; the absence of continuous pain does not make self-diagnosis reliable. The urgency depends on the presentation, not simply on your most recent clinic result. [16]

Sudden facial drooping, weakness of an arm, slurred speech or difficulty finding words can signal a stroke. Sudden loss of vision, one-sided numbness, marked confusion or a severe new headache may also require emergency assessment. Call emergency services immediately, even if the symptoms improve, and do not drive yourself. This is different from arranging a routine review for an established, unchanged nerve symptom. Note the time the person was last known to be well if someone is helping, because the emergency team may ask. You do not have to establish whether vasculitis, a clot or something else is responsible before seeking help. An existing EGPA diagnosis should be communicated, but it must not narrow attention so much that other emergencies are overlooked. Put these instructions in the household emergency plan so another person can act if you cannot explain what is happening. [17]

Bleeding, severe abdominal pain and breathing deterioration

Coughing up blood should be checked promptly, even when it consists of only a few streaks. More than a few spots or streaks, or blood accompanied by difficulty breathing, a very fast heartbeat, or chest or upper back pain, requires emergency care. There are several possible causes, including infections and blood clots, so do not automatically call it an EGPA flare or assume it is harmless irritation from coughing. When contacting a clinician, describe approximately how much blood there was and whether it was mixed with phlegm, but do not delay urgent help to measure or photograph it. Bring your medication list if possible, including any blood-thinning medicine. A previously reassuring scan or improved eosinophil count does not explain a new episode of bleeding. The immediate task is assessment of the current symptom, followed by investigation of its cause. [18]

Sudden severe abdominal pain, pain with marked tenderness, vomiting blood, or black sticky or bloody stool needs urgent emergency assessment. These are not symptoms to manage by experimenting with food restrictions or extra over-the-counter pain medicine. Less dramatic but persistent or worsening pain also deserves clinical advice, particularly when treatment can affect infection risk or the digestive system. Describe the location, onset, relation to meals and any vomiting or change in bowel habit. Tell the clinician which medicines you take and whether a dose was changed recently. Do not assume a medicine is the cause solely because the timing seems to fit, and do not assume every abdominal symptom is vasculitis. Those possibilities require assessment. If you cannot keep prescribed medicines down, contact the treating team promptly for instructions rather than making up a replacement dose or waiting until the next scheduled visit. [19]

Make treatment decisions specific to EGPA and your situation

Mepolizumab: check the indication, not just the brand

In the United States, Nucala, whose active ingredient is mepolizumab, is labelled for treatment of adults with EGPA. Its separate asthma indication includes younger patients, but that does not make the United States EGPA indication a paediatric one. Mepolizumab acts on interleukin-5, a signal involved in eosinophil biology. It is not an emergency rescue treatment for an acute asthma attack. The label warns against abruptly discontinuing systemic or inhaled corticosteroids when starting it. If it is proposed, ask what improvement the team expects to measure, how the existing medicines will be reviewed and which adverse symptoms need reporting. A reduction in one laboratory value is not the only treatment goal. Keep injection instructions, storage advice and the contact for a missed or delayed appointment together, and obtain individual instructions rather than borrowing another patient’s dosing schedule. [20]

European Union authorisation is worded differently. The EMA lists Nucala as an add-on treatment for people aged six years and older with relapsing-remitting or refractory EGPA. In ordinary language, this means disease that returns after improvement or is not adequately controlled with previous treatment. The age range and wording should therefore be checked in the country where care is provided rather than copied from an international discussion. Regulatory authorisation also does not guarantee that a particular health system or insurer will fund the medicine for every patient. Ask the specialist which indication is being used, whether the formulation is appropriate, and what practical arrangements are required. For a child, assessment and prescribing should be led by an experienced paediatric team. An approval statement is information about a product’s permitted use, not evidence that it is the best option for every individual with that diagnosis. [21]

Benralizumab: another option, not a universal replacement

The current United States Fasenra label lists benralizumab for adults with EGPA. It also has separate indications for severe eosinophilic asthma and hypereosinophilic syndrome with different age criteria; those must not be transferred to EGPA. Benralizumab targets the interleukin-5 receptor and affects eosinophils. It is not intended to relieve an acute asthma attack. Starting it does not authorise someone to stop inhaled or oral corticosteroids on their own. Before treatment, ask how its role differs from the medicines already being taken and how the team will decide whether it is helping. Discuss the procedure for possible allergic reactions, missed treatment and any infection-related concerns. Comparing brands only by how often an injection is given misses the more important questions of disease severity, evidence for the situation being treated, safety, local availability and the clinician’s plan for ongoing assessment. [22]

In the European Union, the EMA describes Fasenra as an add-on treatment for adults with relapsing or refractory EGPA. This differs from simply saying that every adult with a new diagnosis should receive it. The relevant discussion is why it fits the current disease pattern and what other treatment is needed. If you see a recommendation written before a newer drug approval, ask the specialist how more recent evidence and authorisation affect the options rather than assuming the older document covers every available medicine. Equally, a newer approval does not erase the need for intensive treatment when organs are threatened. When moving between countries, carry the generic medicine name and the condition for which it was prescribed. Similar packaging or brand recognition is not enough to establish equivalent prescribing rules, supply arrangements or follow-up responsibilities in a new healthcare system. [23]

When stronger immune suppression is needed

Cyclophosphamide is used for some severe autoimmune illnesses and can be part of specialist treatment when EGPA threatens organs. Its monitoring requirements deserve a clear explanation before treatment begins. Possible problems include lowered blood counts, infection, bladder injury and effects on fertility; longer-term risks also need discussion. Ask which blood and urine tests are planned, what symptoms should trigger urgent contact and whether fertility preservation needs to be considered before treatment. The decision may be time-sensitive, so raise reproductive concerns early rather than assuming they can wait until the course is finished. Hydration or bladder-protection instructions must be individualised, especially if there are heart or kidney problems. Do not apply a generic instruction to drink large amounts of fluid when your own team has given a restriction. The aim is to understand the safety plan around a necessary treatment, not to decide its dose or duration independently. [24]

Rituximab is an infusion treatment that changes the activity of part of the immune system. If it is selected for EGPA, ask about the reason for choosing it, the preparations before infusion and the tests needed before and afterwards. Infusion reactions can include itching, rash, throat symptoms, dizziness or breathing problems, so tell the infusion staff immediately about a change rather than trying to tolerate it silently. Infection risk and vaccine timing also need discussion. The exact regimen and monitoring depend on the condition and the person’s circumstances; a schedule found on a general medicine page is not a personal prescription. Keep the infusion dates in your health record and tell other clinicians that you have received it when seeking care later. A medicine given intermittently can still be relevant to a clinical decision long after the day of the infusion. [25]

Maintenance medicines require their own safety routines

Methotrexate is one medicine specialists may use in selected inflammatory disease plans. When it is prescribed for an inflammatory condition, it is commonly taken weekly, not daily. Confirm the exact instructions with the prescriber and pharmacist, including the chosen day and any folic acid prescription. A misunderstanding about frequency is not a small administrative detail. Laboratory monitoring is needed, and the team should explain what to do about fever, mouth sores, unusual bruising or other possible adverse effects. Discuss alcohol, other medicines, supplements and pregnancy plans before treatment rather than assuming an over-the-counter product is automatically compatible. If a new clinician prescribes something, show the complete medication list. The purpose of a written regimen is to make the agreed plan easy to follow and verify, not to create a new schedule from general advice or another patient’s experience. [26]

Azathioprine is another immune-suppressing medicine that may be considered in an individual treatment plan. It can affect blood cells and the liver, and regular blood testing is important even if you feel well. The team may check an enzyme-related test such as TPMT to help assess the risk of toxicity. Ask when the first monitoring sample is due, who receives the result and who will contact you if a change is needed. Mention new abdominal pain, vomiting, fever, unusual bleeding or signs of infection promptly. Drug interactions are particularly important: a pharmacist needs to know about all prescribed and non-prescribed medicines, not just the medicine you consider your main EGPA treatment. If you receive conflicting instructions from different services, request clarification before improvising. A shared, current list reduces the risk that one clinician makes a decision without seeing the rest of the regimen. [27]

Protect yourself while treatment is working

Steroid reductions must be supervised

Prednisolone and related corticosteroids can control inflammation, but stopping suddenly after prolonged or substantial exposure can be dangerous. Your underlying illness may worsen, and the body may not immediately produce enough of its own steroid hormone. A taper is therefore a prescribed plan, not simply a personal test of whether symptoms return. Keep the current dose, tablet strength and next review date written clearly. If instructions change, replace the old schedule so that two conflicting versions are not left in circulation. Contact the team if you miss doses repeatedly, cannot obtain the medicine or cannot keep it down. Do not double a dose or restart an old higher-dose course without advice. Starting another treatment or feeling much better does not by itself mean steroids can be stopped. Ask who is responsible for every reduction when more than one specialist is involved. [28]

Steroid side effects can include sleep disturbance, appetite or weight changes and changes in mood. More serious problems can include infection, high blood sugar and adrenal difficulties. Report symptoms rather than deciding that discomfort must be tolerated until treatment ends. For example, explain whether sleep disruption started after a dose change, whether thirst and urination have increased, or whether you feel unusually low or agitated. The clinician can assess possible causes and consider practical adjustments without sacrificing disease control. It is helpful to distinguish a side-effect discussion from a request to stop treatment immediately. Ask which checks are appropriate for blood pressure, blood sugar and other risks in your circumstances. A balanced plan recognises both why corticosteroids may be needed and why their burden should be reviewed. Never let concern about possible long-term effects delay urgent treatment of an organ-threatening illness. [29]

Bone protection and infection prevention belong in the plan

Long-term glucocorticoid treatment can weaken bones and increase fracture risk. Bone protection is therefore a topic to raise early, not only after pain or a fracture develops. The appropriate assessment depends on age, previous fractures, steroid exposure and other risks. Ask whether a bone density scan, dietary review or preventive medicine is indicated. Calcium and vitamin D requirements should be discussed in the context of your diet, kidney function and any other relevant condition, rather than choosing high-dose supplements independently. Safe movement and falls prevention may also matter, particularly if nerve symptoms affect balance. Tell the team about a low-impact fracture or a new persistent back pain. Bone care should be integrated with the EGPA plan so that someone is clearly responsible for arranging assessment and reviewing results, rather than assuming another clinic has already dealt with it. [30]

Vaccination decisions depend on the medicine, its dose, the degree of immune suppression and the vaccine type. Live vaccines can be unsuitable during substantial immune suppression, while non-live vaccines have different safety considerations and may produce a weaker response in some treatment settings. This is why timing should be discussed with the prescribing team rather than relying on a blanket instruction to avoid all vaccines. Bring the available vaccination record and ask which vaccines are relevant under the current local recommendations. If treatment is urgent, do not delay it on your own to complete a vaccine schedule. Ask how the team balances those priorities and whether a later dose or different timing will be needed. A travel clinic also needs the full medicine list before advising on vaccines. A familiar vaccine name does not guarantee that its timing is appropriate during a new treatment course. [31]

Do not mistake serious infection for a routine flare

A serious infection can worsen quickly. Confusion, slurred speech, difficulty breathing, blue, pale or blotchy skin, or feeling profoundly unwell can be warning signs of sepsis and require immediate medical help. Not everyone has every sign, and a high temperature is not essential to recognise that something is seriously wrong. Tell the emergency service about immune-suppressing medicines and recent treatment. For less severe infection symptoms, use the same-day contact instructions supplied by your team rather than automatically increasing steroids or waiting for a routine appointment. Ask in advance who advises about the next dose of each medicine during an infection, because the answer is not identical for every drug. Keep that advice accessible to anyone helping you. The aim is early assessment of a new illness, not trying to distinguish infection from inflammation using symptoms alone at home. [32]

Turn monitoring into a practical, shared plan

Remission still needs follow-up

Remission means that disease activity has settled; it is not a promise that monitoring can end. Follow-up may include symptom review, blood tests and organ-specific investigations according to the disease pattern and treatment. New symptoms and adverse effects should be discussed even after a period of stability. If you are planning pregnancy, raise this early so the team can assess disease control and medicine suitability together. Do not stop treatment independently in anticipation of pregnancy. A flare may resemble the previous episode or feel different, so the response plan should not depend on reproducing an exact old symptom pattern. Ask what your team means by remission in your case and which findings are still being followed. This makes the next appointment purposeful: you can review disease control, treatment burden and daily function as related but separate parts of care. [33]

A written asthma action plan is useful alongside, not instead of, the EGPA monitoring plan. It should identify daily treatment, how to recognise worsening asthma and what actions to take when symptoms change. If peak flow monitoring is part of your plan, ask for teaching and personalised instructions rather than using another person’s thresholds. Keep the current plan with the names of your inhalers and emergency contact details. One useful appointment question is whether the asthma team and vasculitis team are working from the same medication list. Another is who should be contacted first for a change that is not an emergency. Clear responsibilities can prevent both duplication and gaps. For example, a rise in night-time wheeze may need asthma review while a new weakness or unexplained chest symptom requires a different assessment pathway rather than simply another inhaler adjustment. [34]

Prepare a review that focuses on what matters to you

A new diagnosis can bring relief, uncertainty and a substantial practical workload. Support is useful, but another patient’s successful medicine or recovery timetable cannot determine your own treatment. Before an appointment, choose the three issues most affecting you and write one concrete example for each. You might want to discuss walking to work, sleeping through the night, managing appointments or knowing when to seek help. Ask the clinician to summarise the agreed plan in plain language and repeat it back if any instruction is unclear. With your permission, a trusted person can help take notes or remember questions. Patient support organisations can help with information and coping, while treatment decisions remain with your clinical team. The goal is not to become an expert in every test. It is to leave knowing what happens next, who is responsible and how to get help between visits. [35]

Your monitoring discussion at a glance

Questions to agree with your team, not a universal testing schedule
Area	Bring to the review	Ask the team
Disease activity	A dated account of new or changing symptoms	Which findings show activity, and what else could explain them?
Organ assessment	Previous reports and functional changes	What is our baseline, and what would trigger reassessment?
Medicine safety	Exact names, doses and recent changes	Which tests are due, who checks them, and what happens if I am ill?
Asthma	Inhalers and the current action plan	Is technique correct, and does the plan match my present treatment?
Daily life	Three concrete difficulties or goals	What support, rehabilitation or adjustment could help?
Communication	Contact details for every treating service	Who coordinates decisions and how do I obtain advice between visits?

EGPA: Diagnosis, Monitoring and Care